Inflammation, biomarkers and immuno-oncology pathways in pancreatic cancer
- Details
- Publication Year 2019-04-26,Volume 9,Issue #2,Page pii: E20
- Journal Title
- Journal of Personlised Medicine
- Publication Type
- Journal Article
- Abstract
- It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide management decisions, whether for systemic chemotherapy, molecularly targeted therapies, or immunotherapies. To date, the results for targeted agents and immunotherapies in unselected populations of chemo-refractory pancreatic cancer have not met expectations. The reasons for this lack of efficacy of immunotherapy in pancreatic cancer are not completely understood. The challenges in pancreatic cancer include the physical barrier created by the dense desmoplastic stroma surrounding the tumor, chemokine-mediated exclusion of T cells, relatively poorer antigenicity compared to other solid tumors, paucity of infiltrating T cells within the tumor, ultimately leading to an immunosuppressive microenvironment. A better understanding of the role of inflammation in pancreatic cancer, its tumor microenvironment and individualized patient-related features, be they molecular, clinical or histopathological, would enable a more effective tailored approach to the management of pancreatic cancer. In this review, the role of inflammation, the immune tumor microenvironment and potential immune biomarkers in pancreatic cancer are explored.
- Publisher
- MDPI
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 31035449
- Publisher's Version
- https://doi.org/10.3390/jpm9020020
- Open Access at Publisher's Site
https://doi.org/10.3390/jpm9020020- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-05-08 09:28:16
Last Modified: 2019-05-08 09:37:03